332 related articles for article (PubMed ID: 28472993)
1. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
[TBL] [Abstract][Full Text] [Related]
2. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy.
Congdon EE; Chukwu JE; Shamir DB; Deng J; Ujla D; Sait HBR; Neubert TA; Kong XP; Sigurdsson EM
EBioMedicine; 2019 Apr; 42():157-173. PubMed ID: 30910484
[TBL] [Abstract][Full Text] [Related]
3. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice.
Hovakimyan A; Antonyan T; Shabestari SK; Svystun O; Chailyan G; Coburn MA; Carlen-Jones W; Petrushina I; Chadarevian JP; Zagorski K; Petrovsky N; Cribbs DH; Agadjanyan MG; Ghochikyan A; Davtyan H
Sci Rep; 2019 Oct; 9(1):15455. PubMed ID: 31664089
[TBL] [Abstract][Full Text] [Related]
4. Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer's Disease and Primary Tauopathy Postmortem Brains.
Helboe L; Rosenqvist N; Volbracht C; Pedersen LØ; Pedersen JT; Christensen S; Egebjerg J; Christoffersen CT; Bang-Andersen B; Beach TG; Serrano GE; Falsig J
J Alzheimers Dis; 2022; 88(1):207-228. PubMed ID: 35570492
[TBL] [Abstract][Full Text] [Related]
5. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
6. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
7. Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease.
Gibbons GS; Kim SJ; Wu Q; Riddle DM; Leight SN; Changolkar L; Xu H; Meymand ES; O'Reilly M; Zhang B; Brunden KR; Trojanowski JQ; Lee VMY
Mol Neurodegener; 2020 Nov; 15(1):64. PubMed ID: 33148293
[TBL] [Abstract][Full Text] [Related]
8. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
[TBL] [Abstract][Full Text] [Related]
9. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
10. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.
Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
Roberts M; Sevastou I; Imaizumi Y; Mistry K; Talma S; Dey M; Gartlon J; Ochiai H; Zhou Z; Akasofu S; Tokuhara N; Ogo M; Aoyama M; Aoyagi H; Strand K; Sajedi E; Agarwala KL; Spidel J; Albone E; Horie K; Staddon JM; de Silva R
Acta Neuropathol Commun; 2020 Feb; 8(1):13. PubMed ID: 32019610
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tau binding by gosuranemab.
Sopko R; Golonzhka O; Arndt J; Quan C; Czerkowicz J; Cameron A; Smith B; Murugesan Y; Gibbons G; Kim SJ; Trojanowski JQ; Lee VMY; Brunden KR; Graham DL; Weinreb PH; Hering H
Neurobiol Dis; 2020 Dec; 146():105120. PubMed ID: 32991997
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
Acta Neuropathol Commun; 2017 Jul; 5(1):58. PubMed ID: 28760159
[TBL] [Abstract][Full Text] [Related]
15. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
[TBL] [Abstract][Full Text] [Related]
16. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.
Kontsekova E; Zilka N; Kovacech B; Skrabana R; Novak M
Alzheimers Res Ther; 2014; 6(4):45. PubMed ID: 25478018
[TBL] [Abstract][Full Text] [Related]
17. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
18. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation.
Jeganathan S; Hascher A; Chinnathambi S; Biernat J; Mandelkow EM; Mandelkow E
J Biol Chem; 2008 Nov; 283(46):32066-76. PubMed ID: 18725412
[TBL] [Abstract][Full Text] [Related]
19. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
20. [Human tau N-terminal domain-specific monoclonal antibodies: screening and application in blood detection].
Yan Z; Zhang Y; Jiang J; Liu Z; Wang H; Zhang Y; He J; Hong T
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1571-1583. PubMed ID: 38783817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
